---
id: HIV-basics_109
category: organisms
tags: [HIV, AIDS, antiretroviral-therapy, ART, opportunistic-infections]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## HIV Basics

**Q:** What are the stages of HIV infection, AIDS-defining conditions, principles of antiretroviral therapy (ART), and when to start prophylaxis for opportunistic infections?

**A:**

## OVERVIEW

**Virus:** Human Immunodeficiency Virus (HIV-1, HIV-2)

**Transmission:** Sexual, blood, perinatal

---

## STAGES OF HIV INFECTION

| **Stage** | **Timing** | **Clinical Features** |
|-----------|------------|-----------------------|
| **Acute HIV** | 2-4 weeks post-exposure | **Acute retroviral syndrome:** Fever, rash, lymphadenopathy, pharyngitis<br>**High viral load**, CD4 may drop transiently |
| **Chronic/Latent** | Years (untreated) | Asymptomatic (CD4 gradually declines ~50-100 cells/year) |
| **AIDS** | CD4 <200 OR AIDS-defining condition | Opportunistic infections, malignancies |

**Key Point:** **AIDS = CD4 <200** OR AIDS-defining condition

---

## AIDS-DEFINING CONDITIONS (Key Examples)

| **CD4 Count** | **Opportunistic Infections** |
|---------------|------------------------------|
| **<200** | **PCP** (Pneumocystis jirovecii pneumonia)<br>**Esophageal candidiasis** |
| **<100** | **Toxoplasmosis** (CNS)<br>**Cryptococcal meningitis** |
| **<50** | **CMV retinitis**<br>**MAC** (Mycobacterium avium complex) disseminated |

**Malignancies:**
- **Kaposi sarcoma** (HHV-8)
- **Non-Hodgkin lymphoma** (primary CNS lymphoma)
- **Cervical cancer** (invasive)

**Key Point:** **Lower CD4 → more severe OIs**

---

## ANTIRETROVIRAL THERAPY (ART)

**Goals:**
- **Suppress viral load** (<50 copies/mL)
- **Restore CD4 count**
- **Prevent transmission**

**When to Start:** **ALL HIV-infected patients** (regardless of CD4 count)

---

### **Preferred Regimens (2024):**

**Integrase Strand Transfer Inhibitor (INSTI)-Based (Preferred):**

| **Regimen** | **Components** |
|-------------|----------------|
| **Biktarvy** | **Bictegravir/tenofovir AF/emtricitabine** (1 tablet daily) |
| **Dovato** | **Dolutegravir/lamivudine** (1 tablet daily - if HIV RNA <500K, no HBV) |
| **Trium eq** | **Dolutegravir/abacavir/lamivudine** (1 tablet daily - if HLA-B\*5701 negative) |

**Key Point:** **INSTIs = preferred** (high barrier to resistance, well-tolerated, once-daily)

---

### **Monitoring:**

**Baseline:**
- **HIV RNA** (viral load), **CD4 count**
- **Resistance testing** (genotype)
- **HLA-B\*5701** (if considering abacavir)
- **HBV/HCV** serology
- **Renal/hepatic function**

**Follow-Up:**
- **HIV RNA:** 2-4 weeks, then 4-8 weeks, then **every 3-6 months** (goal: undetectable <50 copies/mL by 12-24 weeks)
- **CD4 count:** Every 3-6 months (can stop monitoring if consistently >300-500 on ART)

**Key Point:** **Undetectable = untransmittable (U=U)**

---

## OPPORTUNISTIC INFECTION PROPHYLAXIS

| **OI** | **CD4 Threshold** | **Prophylaxis** | **Discontinue When** |
|--------|-------------------|-----------------|----------------------|
| **PCP** | **<200** | **TMP-SMX 1 DS tablet PO daily** | CD4 >200 x ≥3 months on ART |
| **Toxoplasmosis** | **<100** (Toxo IgG+) | **TMP-SMX 1 DS tablet PO daily** (same as PCP) | CD4 >200 x ≥3 months on ART |
| **MAC** | **<50** | **Azithromycin 1200 mg PO weekly** | CD4 >100 x ≥3 months on ART |
| **Cryptococcus** | No routine prophylaxis | - | - |

**Key Point:** **TMP-SMX prevents both PCP AND Toxo**

---

## POST-EXPOSURE PROPHYLAXIS (PEP)

**Indication:** High-risk exposure (needlestick, sexual assault, condomless sex with HIV+ partner)

**Timing:** **Start within 72 hours** (ideally <2 hours)

**Regimen:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Tenofovir DF/emtricitabine (Truvada)** | **1 tablet PO daily** | **28 days** |
| **PLUS Dolutegravir OR Raltegravir** | **50 mg PO daily** OR **400 mg PO BID** | 28 days |

**Follow-Up:** HIV testing at 4-6 weeks, 3 months, 6 months

---

## PRE-EXPOSURE PROPHYLAXIS (PrEP)

**Indication:** High-risk HIV-negative individuals (MSM, IVDU, serodiscordant couples)

**Regimen:**

| **Agent** | **Dosing** | **Efficacy** |
|-----------|------------|--------------|
| **Tenofovir DF/emtricitabine (Truvada)** | **1 tablet PO daily** | **>90%** (if adherent) |
| **Tenofovir AF/emtricitabine (Descovy)** | **1 tablet PO daily** | >90% (NOT for receptive vaginal sex) |
| **Cabotegravir LA (Apretude)** | **600 mg IM monthly x 2 → every 2 months** | >99% |

**Key Point:** **Adherence critical** for PrEP efficacy

**Monitoring:** HIV/STI testing every 3 months, renal function

---

**Clinical Pearls:**
- **AIDS = CD4 <200** OR AIDS-defining condition
- **Start ART in ALL HIV patients** (regardless of CD4)
- **INSTIs = preferred ART** (bictegravir, dolutegravir)
- **Undetectable = untransmittable (U=U)**
- **TMP-SMX prevents PCP + Toxo** (start if CD4 <200)
- **PEP within 72 hours** of high-risk exposure (28 days)
- **PrEP >90% effective** if adherent (daily tenofovir/emtricitabine)

**Media:** None

**Sources:** [DHHS 2024 - HIV treatment guidelines]
